OBJECTIVE -Antioxidant trials have not demonstrated efficacy in slowing cardiovascular disease but could not rule out benefit for specific patient subgroups. Antioxidant therapy reduces LDL oxidizability in haptoglobin 1 allele homozygotes (Hp 1-1), but not in individuals with the haptoglobin 2 allele (Hp 2-1 or Hp 2-2). We therefore hypothesized that haptoglobin type would be predictive of the effect of vitamin therapy on coronary atherosclerosis as assessed by angiography.
O
xidative stress is enhanced within the wall of atherosclerotic arteries (1-3). There exists considerable evidence from animal studies that antioxidant vitamins can slow or prevent the development of atherosclerotic lesions (4, 5) . Numerous mechanisms have been demonstrated for this protective effect including the prevention of LDL oxidation within the vessel wall (6) . However, in humans, antioxidant therapy has not been shown to slow the progression of atherosclerotic coronary artery disease (7) (8) (9) . On the contrary, several prospective angiographic studies have demonstrated that antioxidant therapy may be associated with a more rapid progression of atherosclerosis, potentially due to a deleterious effect on the lipid profile (8, 10, 11) or perhaps the ability of these antioxidants to become pro-oxidants under certain conditions (12) (13) (14) (15) (16) (17) (18) .
This discrepancy between the animal and human studies may be the result of functional differences in polymorphic loci, which modulate oxidative stress. Haptoglobin is an antioxidant protein by virtue of its ability to prevent hemoglobin-induced tissue oxidation (19, 20) . The haptoglobin gene locus at chromosome 16q22 is polymorphic, with two general classes of functionally distinct alleles denoted 1 and 2 (21) . This polymorphism exists only in man. The 1 allele in humans is Ͼ90% homologous to the 1 allele existing in all other animals. The 2 allele is present only in humans and is believed to have arisen from the 1 allele ϳ100,000 years ago, early in human evolution (21) . The relative frequency of the two haptoglobin alleles varies by ethnicity and race, thereby accounting for the marked differences observed in the distribution of the three possible haptoglobin types (1-1, 2-1, and 2-2) among different ethnic and racial groups. For example, in American Caucasians, 14% of the population is Hp 1-1 and 37% is Hp 2-2, whereas in American blacks 26% of the population is Hp 1-1 and 38% is Hp 2-2 (22) .
The role of the haptoglobin type on the resistance of LDL to oxidation after antioxidant therapy was recently reported (23) . Although there were no differences in the oxidizability of LDL between study participants with the different haptoglobin types before commencement of the study, after treatment with antioxidants, participants homozygous for the haptoglobin 1 allele (Hp 1-1) had a dramatic increase in the resistance of LDL to oxidation. However, no effect was seen in individuals homozygous for the haptoglobin 2 allele (Hp 2-2) or the heterozygote (Hp 2-1) (23) .
Taken together, these studies suggest that the beneficial effect of antioxidant supplementation on progression of coronary artery disease may be limited to those individuals homozygous for the haptoglobin 1 allele. We have sought to test this hypothesis using plasma samples from the Women's Angiographic Vitamin and Estrogen (WAVE) study (9) , a prospective angiographic study of antioxidant vitamins with or without hormone replacement therapy (HRT) in postmenopausal women.
RESEARCH DESIGN AND METHODS

Description of the WAVE study
The design and methods of the WAVE trial have been previously described (9) . Briefly, WAVE was a prospective, randomized, double-blind trial that enrolled 423 postmenopausal women with at least one 15-75% coronary stenosis at baseline coronary arteriography. Patients were randomly assigned in a 2 ϫ 2 factorial design to receive either 0.625 mg/day of conjugated equine estrogen (plus 2.5 mg/ day of medroxyprogesterone acetate for women who had not had a hysterectomy), matching placebo and 400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily, or placebo. The mean interval between angiograms was 2.8 Ϯ 0.9 years. The main outcome measure of the trial was the annualized mean change in the minimum luminal diameter (MLD) from baseline to the concluding angiogram of all qualifying coronary lesions averaged for each patient. WAVE qualifying segments were defined as segments with 15-75% stenoses at baseline or new lesions at follow-up. The annualized mean change in the MLD from baseline to concluding angiogram (or to intercurrent angiogram before revascularization) was available for all WAVE qualifying lesions and averaged for each patient. Stored plasma from the baseline exam was available on 403 of 423 (95.2%) of the initial WAVE cohort.
Haptoglobin phenotyping
Haptoglobin phenotyping was performed from 10 l of plasma by polyacrylamide gel electrophoresis according to established methods (24) . A signature banding pattern is obtained from individuals who are homozygous for the 1 allele (Hp 1-1) , homozygous for the 2 allele (Hp 2-2), or heterozygous at the haptoglobin locus (Hp 2-1). We have established 100% concordance between the haptoglobin phenotype as determined from plasma and the haptoglobin genotype as determined from genomic DNA by the polymerase chain reaction (25) . Haptoglobin phenotyping was performed with no knowledge of the patient's treatment status.
Statistical analysis
The Hardy-Weinberg principle of population genetics is used to determine whether two alleles are in a balanced equilibrium, indicating a lack of survival benefit for one allele relative to the other. To determine whether a population is in Hardy-Weinberg equilibrium, it is necessary to use the Hardy-Weinberg formula to calculate the genotype frequencies in the population. In this equation (p 2 ϩ 2pq ϩ q 2 ϭ 1), p is defined as the frequency of the 1 allele and q is defined as the frequency of the 2 allele for a trait or phenotype controlled by a pair of alleles (1 and 2). In this equation, p 2 is the frequency of homozygous (1-1) individuals in a population, 2pq is the frequency of heterozygous (2-1) individuals, and q 2 is the frequency of homozygous 2 (2-2) individuals. To actually determine whether our study population was in Hardy-Weinberg equilibrium, the actual distribution of the three haptoglobin types in this study was compared with the distribution of the three haptoglobin types expected if the population was in Hardy-Weinberg equilibrium according to 2 test (26). All analyses were performed using SAS statistical software (version 8.0; SAS Institute, Cary, NC). ANCOVA or 2 tests (as appropriate) compared baseline characteristics of patients segregated according to haptoglobin phenotype. Student's t test was used to compare change in HDL and LDL. The effect of haptoglobin type on change in MLD was analyzed by an ANCOVA model. The differential effect of antioxidant therapy on changes in the MLD in individuals with the different haptoglobin phenotypes was assessed by an ANCOVA model, and the mean changes and SDs in each group were calculated. The baseline covariates, representing known cardiovascular disease risk factors and glycemic control, of age, hypertension, cholesterol level, diabetes status, and HbA 1c were included in all models. Univariate regression with MLD as a dependent variable against HRT as well as against the hormone-vitamin interaction was not statistically significant, and, therefore, HRT was not included in the models presented. We cannot distinguish between WAVE participants with type 1 and 2 diabetes because this information was not obtained upon enrollment in WAVE and is not in the WAVE database.
RESULTS
Characteristics of the WAVE participants who had haptoglobin phenotyping and repeat angiography There were originally 423 women enrolled in the WAVE trial, 154 of which had diabetes. The analyses presented here were performed only on those 299 participants (113 of whom had diabetes) for whom both repeat angiography and a haptoglobin type was obtained. The number of participants for whom repeat angiography and/or haptoglobin phenotype was obtained is described in Table 1 . The distribution of the haptoglobin types of those individuals who enrolled in WAVE but did not undergo repeat angiography was not different from those who did undergo repeat angiography.
In the population undergoing repeat angiography, the distribution of the three haptoglobin phenotypes in the entire cohort and in those individuals with diabetes was in Hardy-Weinberg equilibrium. There were no significant differences in the entire cohort or in the diabetic subgroup with respect to baseline demographic, angiographic, or clinical characteristics in participants with the three different haptoglobin phenotypes (Table 2) .
Changes in the MLD as a function of haptoglobin phenotype
In the entire study population, there was no difference in the change in MLD based on haptoglobin phenotype (P ϭ 0.19). The average (ϮSD) change in MLD was Ϫ0.047 Ϯ 0.199 for Hp 1-1, Ϫ0.026 Ϯ 0.110 for Hp 2-1, and Ϫ0.048 Ϯ 0.153 for Hp 2-2.
In the diabetic study population, there also was no difference in the change in the MLD based on haptoglobin phenotype (P ϭ 0.12). The average (ϮSD) change in MLD was Ϫ0.071 Ϯ 0.207 for Hp 1-1, Ϫ0.037 Ϯ 0.100 for Hp 2-1, and Ϫ0.110 Ϯ 0.188 for Hp 2-2.
Changes in the MLD as a function of haptoglobin phenotype and vitamin therapy The means and SDs for each vitamin/ haptoglobin type, both before and after adjustment for baseline covariates, are shown in Table 3 . Vitamin supplementation had a differential effect on MLD after adding a vitamin use/haptoglobin type interaction into the model (P ϭ 0.035 for the interaction term between haptoglobin type and vitamin use on the change in the MLD). There was a significant benefit acquired on the change in the MLD with vitamin therapy as compared to placebo in individuals with Hp 1-1 (P ϭ 0.049), whereas there was no significant benefit seen in Hp 2-1 and Hp 2-2 individuals. In Hp 2-2, there was a nonsignificant trend suggesting a negative effect of vitamin therapy compared with placebo. After adjusting for baseline covariates (age, hypertension, cholesterol, and diabetes status), the relative benefit or harm of vitamin therapy in Hp 1-1 or Hp 2-2 individuals, as compared with placebo, was unchanged. The means and SDs for each vitamin/haptoglobin type in the diabetic cohort, both before and after adjustment for baseline covariates, are shown in Table  3 . This interaction of haptoglobin phenotype and vitamin therapy upon coronary artery stenosis progression was even more pronounced in the diabetic cohort (P ϭ 0.003 for the interaction term between haptoglobin type and vitamin use on the change in the MLD). Not only was there a significant benefit demonstrated from vitamin therapy compared with placebo in Hp 1-1 individuals, but there was also a significant deleterious effect on MLD in those individuals with Hp 2-2 both before and after adjustment for baseline covariates (age, hypertension, cholesterol, and HbA 1c ) compared with placebo. Moreover, we found a statistically significant trend effect between the number of haptoglobin 1 alleles and the change in MLD in diabetic subjects who were on vitamin therapy. In this group, the change in MLD had a significant linear association with the number of haptoglobin 1 alleles as described by linear regression analysis with adjustment for baseline covariates (P ϭ 0.005). HRT had no effect on these outcome measurements, and univariate regression with MLD as a dependent variable against the HRT-vitamin interaction was not statistically significant.
Changes in lipid profile with vitamin therapy
Previous studies have suggested that antioxidant therapy may have a negative impact on the lipid profile and on the activity of lipid-lowering drugs (8, 11) . In the entire cohort, there was no significant difference in the change in LDL or HDL during the course of the study in those individuals receiving vitamin therapy or placebo. Moreover, there was no significant difference in the net change in LDL or HDL in any haptoglobin subgroup with or without diabetes (Table 4) .
CONCLUSIONS -Although antioxidant therapy in animals has shown promise in slowing the progression of atherosclerotic lesions (4,5), prospective angiographic studies in humans have failed to corroborate these findings (7) (8) (9) . In the original report of the overall results from the WAVE study, antioxidant vitamins were not shown to provide cardiovascular benefit; instead, a potential for harm was suggested (9) . We have demonstrated one possible explanation for this paradox here, namely that the benefit of antioxidant therapy with vitamin C and E on progressive coronary artery stenosis may be restricted to women with the Hp 1-1 phenotype. These data are consistent with recent studies showing that antioxidant therapy only had a significant effect in lowering of LDL in Hp 1-1 individuals (23) . It should be stressed that these findings were most prominent in diabetic subjects. Furthermore, only ϳ17% of the original cohort (Hp 1-1 individuals) could have derived benefit from vitamin C and E therapy, whereas ϳ37% of the original cohort (Hp 2-2 individuals) could have experienced harm from vitamin C and E therapy. Why might vitamin E and vitamin C therapy be harmful in some haptoglobin types? Our results do not support a mechanism based on vitamin-induced differences in the lipid profile (8, 11) . One potential explanation is related to the prooxidant capacity of vitamin C in the presence of iron (12, 14, 16, 17) . Vitamin C promotes the reduction of Fe 3ϩ to Fe 2ϩ and consequently promotes the formation of hydroxyl radicals by the Fenton reaction (12, 14) . In the process, vitamin C is oxidized to dehydroascorbate and becomes a pro-oxidant. Serum levels of iron are highest in Hp 2-2 individuals (27) . Serum levels of vitamin C are also dependent on haptoglobin type; the lowest levels occur in Hp 2-2 individuals (28). It has been proposed that the lower levels of vitamin C in Hp 2-2 individuals are due to an increased oxidation of vitamin C (28) . Supplemental vitamin C may not be beneficial to individuals with Hp 2-2 because it may result in increased production of oxidized vitamin C. The fundamental reason why vitamin C is more rapidly consumed and converted into a pro-oxidant in Hp 2-2 individuals is not altered by vitamin therapy. Why should the haptoglobindependent effect of vitamin therapy on angiographic stenosis be more pronounced in the WAVE diabetic subgroup? Hyperglycemia results in a marked increase in oxidative stress and directly enhances LDL oxidation (29) . Mowri et al. (30) have shown that this glucose-enhanced oxidation of LDL is strictly metal-ion dependent. Similar to vitamin C, glucose auto-oxidation results in the reduction of Fe 3ϩ to Fe 2ϩ (30) , thereby enhancing the ability of Fe to serve as a Fenton reagent and produce hydroxyl radicals. As haptoglobin typedependent differences in oxidative stress and redox active iron seem to be most prominent in the diabetic state (20) and vitamin C therapy may be synergistic with hyperglycemia in promoting LDL oxidation via the Fenton reaction as discussed above, vitamin C supplementation in individuals with hyperglycemia and Hp 2-2 may be particularly deleterious.
Limitations in the WAVE study suggest caution in extrapolating these results immediately to the clinical arena at the present time. First, ϳ20% of the original cohort recruited did not undergo follow-up angiography and only 84% of the Vitamins, haptoglobin, and atherosclerosis patients assigned to the vitamin group actually took the drug, which may have produced a selection bias (9) . Second, the primary end point of the WAVE study was coronary artery dimensions and not coronary events. Although coronary progression has been shown in previous angiographic trials to be a strong, independent predictor of future coronary events (31), the culprit coronary artery lesion in coronary events does not correlate well with the lesion that was most stenosed on an antecedent angiogram. Third, systemic markers of oxidative stress were not measured in WAVE; therefore, the efficacy of the antioxidant vitamins in reducing oxidation cannot be assessed (1) . Fourth, the formulation of antioxidant vitamins used in WAVE was quite different from that used in other antioxidant trials (32, 33) . Whereas WAVE participants received 400 IU of vitamin E and 500 mg of vitamin C twice daily, in the Heart Outcomes Prevention Evaluation (HOPE) study (32) , participants received only 400 mg of vitamin E once daily, and in the Heart Protection Study (HPS) (33) , participants received 600 mg of vitamin E, 250 mg of vitamin C, and 20 mg of ␤-carotene once daily. A final limitation is that this is a subgroup analysis, resulting in significantly smaller groups for comparison, especially in the diabetes subgroup, which has a small sample size for Hp 1-1. Despite these limitations, the current study suggests that it would be prudent to reexamine several of the recent large antioxidant cardiovascular disease prevention studies for possible benefit of antioxidant therapy to certain patient subgroups based on the haptoglobin type (32, 33) . If the findings presented here are validated in such studies, haptoglobin typing may become a useful tool to identify individuals who will benefit from antioxidant therapy.
